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Abstract 
 
Chondroitin sulphate glycosaminoglycan chains on cell and ECM proteoglycans can no longer be 
regarded as merely hydrodynamic space fillers. Overwhelming evidence over recent years 
indicates that sulphation motif sequences within the chondroitin sulphate chain structure are a 
source of significant biological information to cells and their surrounding environment. 
Chondroitin sulphate sulphation motifs have been shown to interact with a wide variety of 
bioactive molecules e.g. cytokines, growth factors, chemokines, morphogenetic proteins, enzymes 
and enzyme inhibitors, as well as structural components within the extracellular milieu. They are 
therefore capable of modulating a panoply of signalling pathways thus controlling diverse cellular 
behaviours including proliferation, differentiation, migration and matrix synthesis. Consequently, 
through these motifs, chondroitin sulphate proteoglycans play significant roles in the maintenance 
of tissue homeostasis, morphogenesis, development, growth and disease. Here we review (i) the 
biodiversity of chondroitin sulphate proteoglycans and their sulphation motif sequences and (ii) 
the current understanding of the signalling roles they play in regulating cellular behaviour during 
tissue development, growth, disease and repair. 
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1. Introduction 
 
 Chondroitin sulphate (CS) and its sulphation motifs on cell associated, pericellular and 
extracellular matrix (ECM) proteoglycans (PGs) represent a significant repository of information in 
tissues with the capacity to encode functional information rivalling that of RNA, DNA and proteins 
[1].  This information is realised when CS and its sulphation motifs interact with growth factors, 
cytokines, morphogenetic proteins, enzymes, inhibitors and pericellular matrix (PCM) and ECM 
stabilising glycoproteins. Such interactions have diverse effects on cellular metabolism, 
proliferation and differentiation, cell migration, matrix synthesis/stabilisation and tissue remodelling 
in development and are critical to the cellular control of tissue homeostasis.  CS sulphation motifs 
on cell-associated, PCM and ECM proteoglycans also provide important molecular recognition and 
activity signals to stem/progenitor cell niches facilitating the sequestration of combinations of 
growth factors, cytokines and chemokine’s which maintain the niche microenvironment ensuring 
stem cell survival and their maintenance in a state of quiescent self-renewal within the niche 
environment. Perturbations in the signals which stem cells receive in this niche can also orchestrate 
stem/progenitor cell differentiation and pluripotency resulting in stem cell activation and 
proliferation into specific cell lineages with migratory properties facilitating their participation in 
tissue growth, development and repair processes.   
 
 Virtually every cell in the human body is surrounded by a dense glycocalyx of 
glycoconjugates consisting of mixtures of glycoproteins, proteoglycans and glycolipids which 
provide a protective and interactive barrier [2].  CS is a prominent glycosaminoglycan (GAG) 
component of many of these molecules and is the most abundant GAG in the human body [3]. The 
glycocalyx connects the cell to its external microenvironment and components in the glycocalyx act 
as biosensors through which cells perceive and respond to changes in the environment they live in 
[4, 5]. The endothelial glycocalyx also has mechanosensory shear and compression responsive 
functions, which regulate mechanotransductive effects on endothelial cell signalling and vascular 
permeability, which are important in the nutrition and development of tissues [2, 5-9]. In brain, the 
glycocalyx of microglia and oligodendrocytes contain cell surface sialic acid binding 
immunoglobulin like lectins (SIGLECS), which identify sialic acids in cell surface glycoconjugates 
in adjacent neurons facilitating cellular communication and signalling through an intracellular 
immunoreceptor tyrosine based inhibition motif (ITIM) which maintains a homeostatic balance in 
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neuronal cells [4]. Embryonic stem cells also assemble a glycocalyx containing cell surface epitopes 
which not only can be used to identify specific stages of stem cell differentiation but serve as 
interactive modules that can network with regulatory cues received from the ECM influencing stem 
cell differentiation [2]. The endothelial and epithelial glycocalyx also have important roles to play 
in inflammation and immunomodulation [10].  MUC1 (CD227), a high molecular weight (>400 
kDa) widely distributed, multifunctional, type-1 membrane tethered epithelial glycoprotein, has 
roles in dendritic cells, monocytes, T and B cells in immune mediated inflammatory processes [11].  
MUC1 in the mucosal lining also provides a protective lubricative barrier to microbial infection [12, 
13]. The cerebrovascular glycocalyx also has important roles to play in neural protection; SIGLECS 
protect neurons from acute toxicity through interaction with glycolipids, which provide barrier 
functions [14, 15]. The glycocalyx displays brain specific functions through its participation in 
interactions with cell surface receptors, which undertake protein-phosphorylation mediated 
signalling by neurons and can also influence apoptosis and amyloid deposition [7]. GAG 
components in the glycocalyx have important roles in neuroprotection through interactions with CS-
receptors and participation in cell signalling events which maintain cellular integrity and also 
preserve the tissue hydration provided by GAGs to the PCM and ECM. 
 
2. The biodiversity of ECM and cell associated molecules decorated with CS GAG chains. 
CS (Fig 1) is composed of  1-3 and 1-4 linked D-glucuronic acid and N-acetyl D-galactosamine 
repeat disaccharide units which can be O-sulphated at the 2, 4 and C6 position [16].  Furthermore, 
the D-glucuronic acid moiety may also be epimerised to  -Iduronic acid in the related GAG 
dermatan sulphate (DS) leading to a considerable degree of structural diversity in CS/DS and the 
ability to interact with a large range of cytokines, chemokines, morphogens and growth factors 
which regulate cellular proliferation and differentiation and tissue development [16-25].  CS also 
has indispensable roles to play in stem cell differentiation and the attainment of pluripotency [26] 
 
 CS (Fig 1) decorates a remarkably diverse collection of matrix and cell associated 
macromolecules (Fig 2-4). Their functional properties are summarised in Table 1 and their structural 
features shown diagrammatically in Figs 2-4.  CS occurs as a number of isomeric forms. referred to 
as CS-A, CS-C, or CS-D based on the mono- or disulphate positions (Figure 1j). CS-B, also known 
 5 
as dermatan sulphate, like CS-A is sulphated at the C4 position of N-acetyl D-galactosamine, but 
differs due to epimerization of D-glucuronic acid to L-Iduronic acid and this is sulphated at C2. 
 
2.1 The CS-proteoglycans represent a bio-diverse group of molecules. 
2.1.1 The Hyalectans 
The Hyalectans are a group of large HA interactive CS-proteoglycans [27-31] (Fig 2a). Aggrecan 
and versican form aggregate structures with HA which provide tissues with an ability to act as 
weight bearing and tension resisting structures while neurocan, brevican and aggrecan hyalectans 
form perineural-net structures through interaction with HA and tenascin-R (Fig 5a). Perineuronal 
nets have neuroprotective roles [32, 33] but also inhibit neuronal repair processes by inhibiting 
neurite outgrowth, both of these functions are due to the particular GAGs, which decorate these 
proteoglycans. Similar network structures between aggrecan, link protein and hyaluronan are also 
prominently featured in cartilaginous tissues where they have roles in weight bearing (Fig 5b).  
2.1.2 The SLRPs 
The small leucine rich proteoglycan (SLRP) family have well known functional roles in the 
regulation of collagen fibrillogenesis but have additional cell regulatory roles through their 
interactive properties with cytokines, growth factors and morphogens [34-38] Decorin and 
biglycan are two SLRPs which contain one or two CS chains and in specific contexts DS (Fig 2b).   
2.1.3 SPACRCAN 
SPACRCAN is a novel 400 kDa CS-proteoglycan of the inter-photoreceptor ECM providing an 
interface between the photoreceptors and the pigmented retinal epithelium in the fundus of the eye 
[39]. SPACRCAN contains 6-sulphated CS chains and a number of N- and O-linked 
oligosaccharides which collectively constitute ~60 % of its total mass (Fig 2c) . SPACRCAN has 
two RHAMM like binding domains through which it interacts with HA to form an aggregate 
structure which organises the ECM and is also important in the hydration of this tissue [40].  
 
2.1.4 Perlecan 
Perlecan is a HS-proteoglycan in vascular tissues however chondrocytes and smooth muscle cells 
synthesise a hybrid form of perlecan where CS chains replace some of its HS chains [41-46]. 
Epithelial perlecan is also a hybrid perlecan and a unique proteoglycan containing HS, CS and KS 
chains [47].  The form of perlecan synthesised by foetal IVD progenitor cells contains 7-D-4 CS 
sulphation motifs [48].  The GAG side chains of perlecan in growth plate cartilage contain 
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embedded 4, 6-disulphated CS-E disaccharides that direct collagen fibrillogenesis[49] and are also 
found in the brain proteoglycan, appican interacting with neuroregulatory factors, which direct 
neuritogenesis [50-52].   
 
2.1.5  Appican 
Over sulphated disaccharides of CS-D and CS-E (Fig 1j) regulate neuronal adhesion, cell migration, 
and neurite outgrowth in the CNS. Several brain CS-proteoglycans including phosphacan (DSD-1) 
and bikunin contain embedded CS-D motifs within their CS side chains. Appican is the only brain 
proteoglycan identified, with embedded CS-E [51]. Appican is produced exclusively by astrocytes, 
which regulate neural cell adhesion and outgrowth.  Appican also contains Alzheimer amyloid 
precursor protein (APP) as a core protein component, which is a Kunitz protease inhibitor/Protease 
nexin 2 domain [50] with voltage gated ion channel blocking properties relevant to neurite regulation 
[53]. The CS-E motif is essential for the interaction of the appican CS-chain with 
growth/differentiation factors, and the regulation of neuronal cell adhesion, migration and neurite 
outgrowth. 
 
2.1.6  NG2/CSPG4 
Chondroitin sulphate proteoglycan-4 (CSPG-4) (Fig 3a), also known as high molecular weight 
melanoma associated antigen in humans and nerve-glial antigen-2 (NG2) in rodents is a 
transmembrane CS-proteoglycan expressed by immature progenitor cells including 
oligodendrocyte, chondroblasts/osteoblasts, myofibroblasts, smooth muscle cells, pericytes, 
interfollicular epidermal and hair follicle cells [54, 55].  CSPG4 is a single pass type 1 
transmembrane protein, occurring as a 250kDa glycoprotein, a 450kDa C4S-proteoglycan or can be 
non-glycanated [56, 57].  The CS side chain of CSPG-4 facilitates interactions with 41 integrin 
and fibronectin and has roles in the activation of proMMP2 by transmembrane MMPs. This ability 
to influence integrin and MMP activation implicates CSPG-4 in melanoma migration and invasion 
in skin [58, 59]. CSPG-4 may participate in cell signalling as a co-receptor or by association with 
cytoplasmic kinases such as FAK or ERK-1, 2. CSPG-4 binds FGF-1 and PDGF AA and presents 
these to their cognate receptors to influence cellular proliferation and differentiation [60]. The 
central non-globular domain of CSPG-4 binds to collagen V and VI [61, 62] facilitating cellular 
attachment and ECM stabilisation and may induce cytoskeletal reorganisation conducive to cell 
spreading and migration [63, 64]. In NG2 knockout mice the epidermis is very thin due to reduced 
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basal keratinocyte proliferation  providing clues as to the likely role of this proteoglycan in skin 
development and homeostasis and insightful as to its possible roles in melanoma spread [54, 57].  
 
2.1.7 Thrombomodulin 
Thrombomodulin (TM-, CD141) is a multifunctional 74-105 kDa cell-surface CS-proteoglycan 
mediator of endothelial anticoagulant activity, activator of Protein-C and a thrombin receptor (Fig 
3b).  The presence of CS on TM-
accelerates thrombin inhibition [65, 66]. The C-4-S chains on TM are relatively small (10-12 kDa) 
[67, 68] but essential for its anticoagulant activities [69]. TM acts as an anticoagulant protein through 
its actions on thrombin and by participating in the generation of activated protein C (APC) [66]. 
Once APC is formed it binds to protein-S on the cell surface and the APC-protein-S complex 
inactivates factors Va and VIIIa. [70-72].  TMs domain structure and multi-component interactions 
with thrombin, Protein-C, Thrombin-Activatable Fibrinolysis Inhibitor, Complement, LewisY 
antigen, and HMGB1, a chromosomal protein which regulates transcriptional replication, facilitates 
TM’s physiologically significant anti-inflammatory, anti-coagulant, and anti-fibrinolytic properties 
[73, 74].  
 
2.1.8 Phosphacan 
Receptor-type protein tyrosine phosphatase beta (RPTP-) is a transmembrane CS-proteoglycan 
expressed in the developing nervous system and contains an extracellular carbonic anhydrase 
(CAH) and fibronectin type III repeat domain, both of these domains foster protein-protein 
interactions.  RPTP is expressed in 3 alternatively spliced forms RPTP-, RPTP- , and a 
truncated form of RPTP- with an 860 amino acid deletion (Fig 3c).  Phosphacan is the 
proteolytically released ecto-domain of the transmembrane protein tyrosine phosphatase receptor-
 of neurons and glial cells [75] and is a principal CNS proteoglycan promoting neuron-glial 
interactions, neuronal differentiation, myelination and axonal repair. The transient nature of cell 
signalling by phosphorylation requires specific phosphatases for regulatory control.  
Phosphorylation of tyrosine residues in cellular proteins plays an important role in the control of 
cell growth and differentiation in the brain [76-79]. The complexity of this regulatory system is 
evident in the spectrum and widespread distribution of spatially and temporally expressed  protein 
tyrosine phosphatases. The CAH domain of RPTP-/ -protein 
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recognition, induces cell adhesion and neurite outgrowth of primary neurons, and differentiation 
of neuroblastoma cells.  Interaction of phosphacan with contactin may generate unidirectional or 
bidirectional signals which direct neural development and axonal repair [80].  
 
2.1.9 The Syndecan family 
The GAG side chains of the syndecan proteoglycans provide subtle variation in their binding 
properties with ligands (Fig 3d). The core protein of the syndecans have a protease sensitive site 
close to the transmembrane attachment region, its cleavage results in the release of a soluble ecto-
domain form of these proteoglycans.  Although widely categorised as HS-proteoglycans, syndecan-
1, 3 and 4 can also be substituted with CS chains [81]. HS chains have an invariant structure between 
syndecan family members however their CS chains may contain non-sulphated, 4-O-, 6-O-, and 4,6-
O-disulfated N-acetylgalactosamine-CS-E. The CS chains of syndecan-4 generally display a greater 
overall sulphation level than the CS chains in syndecan-1 [82, 83]. The HS and CS chains of 
syndecan-1 and 4 bind FGF-2, midkine (MK) and pleiotrophin (PTN).  The HS and CS side chains 
of syndecan-4 are found localised with integrins in focal adhesions in fibroblasts indicating that they 
have roles in cellular attachments and promote cellular migration [84] and may also influence cell 
signalling .  
 
2.1.10  CD44 
CD44 is the major HA receptor in the human body and is a ubiquitously distributed cell surface 
receptor (Fig 3e).  CD44 can also occur as a part-time proteoglycan called epican, which is 
substituted with HS or CS chains.  Epican is expressed by keratinocytes and mediates cell adhesive 
properties between keratinocytes in the epidermis [85, 86]. 
 
2.1.11 Bikunin 
Bikunin is a 30-39 kDa serum proteinase inhibitor synthesized in the liver and is a member of the 
inter--trypsin inhibitor  (220 kDa) (ITI) and pre--trypsin inhibitor (125 kDa) (Pre--TI) families 
[87, 88] (Fig 4a).  A retrospective assessment of the Kunitz serine proteinase inhibitory proteins 
present in ovine articular cartilage, meniscus and intervertebral disc indicated that the 250, 120, 86, 
58, 34-36 and 6-12 kDa SPIs in these tissues were related to ITI and pre--TI [89, 90]. Bikunin’s 
CS chains contain regions which are sulphated and non-sulphated, the sulphated region contain 
embedded CS-D disaccharides [91].  The CS chain in bikunin is relatively small but heterogenous 
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(8-25 kDa) [92, 93]. Bikunin inhibits trypsin, thrombin, chymotrypsin, kallikrein, plasmin, elastase, 
cathepsins, Factors IXa, Xa, XIa, XIIa inhibitory activity and contains two 6 kDa Kunitz inhibitory 
domains. Bikunin counters inflammatory processes during a number of physiological processes and 
also has anti-tumour and anti-viral and neuroregulatory activities. 
 
2.1.12 Type IX collagen 
Type IX collagen [94, 95] contains a CS chain attached to the 2-chain of the type IX NC3 domain 
[96-98] and is the PG-Lt proteoglycan isolated from chick embryonic tibia and femur [99] and chick 
embryo sternal cartilage [100, 101] (Fig 4b).  CS-substituted type IX collagen has also been isolated 
from chondrosarcoma [102] but is present as a minor glycanated form in articular cartilage [103].  
The Type IX collagen of chick vitreous humour contains an extraordinarily large CS chain of 
350kDa in size [104-107]. The related type XII [108, 109] and XIV collagen [110] which are 
basement membrane components, also bear CS chains and homology to type IX collagen.  
 
2.1.13 Testican 
The SPOCK gene encodes the protein core of a seminal plasma testican proteoglycan containing 
CS- and HS chains (Fig 4c). This protein's function is unknown, although similarity to thyropin-
type cysteine protease-inhibitors suggests its function may be related to protease inhibition. 
Testican-1 inhibits cathepsin-L [111]. Testican-2, 3 also regulates MMP activation at the cell surface 
abrogating MT1 MMP activity and proMMP-2 processing [112, 113]. Testican is produced by 
endothelial cells [114] and has a widespread distribution, the brain is a particularly rich source of 
testican [115].  
 
2.1.14  Serglycin 
Serglycin is the only intracellular proteoglycan so far identified.  Serglycin localizes to the α-
secretory granules of platelets and mast cells, where it binds and regulates the activity of platelet 
factor-4 in platelets or tryptase and chymase in mast cells [116-119]. Serglycin is decorated with CS 
chains in the secretory granules of circulating basophils, but with heparin in resident tissue mast 
cells [116, 120]. Mast cell serglycin displays a 2-B-6 (-) epitope on the CS chains which decorate 
this proteoglycan [121].  Trypstatin, the Kunitz protease inhibitor domain 2 of bikunin/ITI is 
localized complexed with serine proteases in the granules of mast cells. 
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2.1.15  Colony stimulating factor 
Human monocytes secrete two CS-proteoglycan forms of colony stimulating factor (CSF) 
containing two CS chains attached at the C-terminus of CSF-1 [122, 123].   
 
2.1.16  Leprecan 
Leprecan is a basement membrane CS-proteoglycan; it contains an N-terminal leucine and proline 
rich domain, a C-terminal globular domain containing two CS chains and a 2-oxoglutarate-Fe 
dependant dioxygenase and prolyl-3-hydroxylase enzymatic activity [124]. Prolyl hydroxylases 1-
3 (PHD1-3) are oxygen-sensing enzymes which catalyse the hydroxylation of 
conserved prolyl residues in the HIF-1 sub-unit in normoxia targeting it for proteasomal 
degradation. HIF-1 and NF-κB are stabilised in hypoxia regulating a diverse range of ~200 genes 
in erythropoiesis, angiogenesis, cardiovascular function, inflammation, apoptosis and cellular 
metabolism [125-128].   
 
2.1.17  Identification of neuroendocrine Pro-hormones as CS-Proteoglycans. 
A number of CS-DS pro-hormones have been identified using a proteomics screen involving 
isolation by anion exchange chromatography, pre-digestion of the isolated anionic proteins with 
chondroitinase ABC and identification of the CS linkage tetrasaccharide by mass spectrometry. 
Many of these pro-hormones are stored in intracellular granules in neuroendocrine cells.  Granule 
proteins such as Chromogranin-A are processed into hormone peptides such as secretogranin-1, 2, 
3, cholecystokinin or neuropeptide W.  
 
3. Aggregated proteoglycan structures in cartilage and brain. 
Members of the hyalectan proteoglycan family including aggrecan, brevican, neurocan and versican 
form massive supramolecular perineural net structures in the CNS  (Fig 5a) through interactions 
with HA and tenascin-R.  Perineural nets protect neurons from oxidative stress and mechanical 
damage but also provide inhibitory signals preventing neural outgrowth.  Aggrecan and versican 
also form massive supramolecular aggregate structures by interaction with HA and link protein in 
cartilage and fibrocartilaginous tissues (Fig 5b).  These aggregated structures have impressive water 
regain properties equipping cartilage and IVD with the ability to withstand compressive forces. 
 
4. CS sulphation motifs as molecular markers of tissue morphogenesis 
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 During tissue morphogenesis several proteoglycans contain native 4-C-3, 7-D-4, 3-B-3[-] 
and 6-C-3 sulphation motifs (see Fig 1 for explanation).  These native CS sulphation motifs are 
expressed in the surface regions of developing articular cartilages in the knee joint (Fig 6 a, b) 
perichondrial growth plate, and in vascular ingrowth and stromal vascular niches of transitional 
tissues associated with diarthrodial joint and IVD development.[129-132]. Confocal colocalisation 
of the aforementioned CS sulphation motifs with aggrecan, versican and perlecan in neonatal 
cartilages has demonstrated that aggrecan and perlecan in these tissues bear these sulphation motifs 
while versican does not [133].  Confocal studies in the human foetal elbow also demonstrated 
perlecan associated with perichondrial stem cell niches (Fig 7a) and with progenitor cell populations 
in the perichondrium (Fig 7c, g) and surface regions of the developing elbow joint cartilages (Fig 
7c, h, i).  
 
4.1 Cartilage proteoglycans containing CS sulphation motifs with roles in tissue development.  
 Aggrecan is the major CS-proteoglycan of cartilaginous tissues, with well-known space-
filling and water imbibing properties that equip these tissues with resilience to compressive 
loading. Correct sulphation of CS-proteoglycans is essential for proper Indian hedgehog signalling 
in the developing growth plate [134], perlecan, a hybrid CS-HS proteoglycan in cartilage is also 
responsible for the localization and activity of the related Sonic hedgehog protein [135]. Native 
CS sulphation motifs such as 7-D-4 on proteoglycans may serve to immobilise growth 
factors/morphogens actively involved in tissue development [17].  The unique distributions of 
native CS motifs such as 7-D-4 with surface zone progenitor cells in articular cartilage [132, 136, 
137] and within the developmental intervertebral disc (IVD) [129] and human foetal elbow [130] 
is suggestive of an early stage of progenitor cell differentiation and indicates that native CS 
sulphation motifs have functional roles in chondrogenesis and in IVD development [129, 136, 
137].. 
 
4.2 Focal expression of the 7-D-4 CS sulphation motif in human foetal paraspinal blood vessels.  
 Perlecan produced by endothelial and smooth muscle cells is a prominent component of 
capillaries and larger blood vessels (Fig 8a, b). The 7-D-4 CS sulphation motif displays a focal 
distribution in the lumenal surfaces of capillaries and between the endothelial cells lining human 
foetal paraspinal blood vessels (Fig 8b).  Pericytes are contractile cells that wrap around the 
abluminal surface of endothelial cells that line the capillaries and venules throughout the body (Fig 
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8d-g).  Caplan proposed that all stem cells were pericytes emphasising their vascular origins [138-
141].  Pericytes are embedded in basement membrane where they communicate with endothelial 
cells of the body's smallest blood vessels by means of both direct physical contact and paracrine 
signalling [142-145].  Blood flow generated shear forces are also important functional determinants 
of the differentiation of stem cells in the luminal surfaces of blood vessels [8, 146].  
 
4.3 The tissue distribution and function of oversulphated CS isomers CS-D and CS-E 
 Developmental studies on the whole rat brain have correlated changes in the CS side chain 
structure of phosphacan with measurable changes in the binding affinity of PTN and functional 
consequences on the cell signalling response.  Phosphacan isolated from whole rat brain from 
various developmental stages was examined using the CS antibodies MO225, CS56 and 2H6 in a 
plasmon resonance study [147]. P7-phosphacan strongly reacted with CS56 and 2H6 but not 
MO225. P12-phosphacan showed moderate reactivity with CS56 and 2H6 but no reactivity to 
MO225 contrasting with P20-phosphacan which was strongly reactive with MO225 but low 
reactivity with CS56 and 2H6.  mAb 2H6 is sold as an anti CS-A Ab due to its high reactivity with 
whale cartilage CS-A however its reactivity with phosphacan of a defined CS-A content does not 
correlate with this.  P7 phosphacan with a CS-A content of 64% had the highest reactivity with mAb 
2H6 while P20 phosphacan with a CS-A content of 86% had very low reactivity.  This showed that 
the 2H6 epitope was not to a simple CS-A unit but to a more extended binding epitope. Subsequent 
studies have shown that mAb CS-56 and MO-225 specifically recognize octasaccharides containing 
an A-D tetrasaccharide sequence, whereas 2H6 preferred sequences with A- and C-units such as C-
C-A-C for strong binding but no D-unit, mAb MO225 also recognised the CS-E disaccharide motif 
from squid cartilage in an extended E-E-E-E-C binding motif [148, 149].  The development of CS 
oligosaccharide libraries [150] of defined structure has further enhanced the precision of such 
structure-function studies. These show that the CS motifs are differentially regulated in brain 
development and modulation in CS structure occurs in a spatiotemporal manner. 
 
5. Cell regulatory proteoglycans are involved in neural development and repair. 
 Oversulphated CS/DS promotes neural development with variation in sulphation profiles 
of proteoglycans regulating vertebrate CNS development. The disulphated disaccharide D-unit 
promotes neurite outgrowth through the DSD-1 epitope embedded in the CS chains of DSD-1-
PG/phosphacan [150-155].  Oversulphated DS displays neurite outgrowth activity [156]. The short 
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isoform, non-proteoglycan variant form of phosphacan/receptor protein tyrosine phosphatase- also 
interacts with neuronal receptors and promotes neurite outgrowth [80]. Bikunin is also expressed in 
brain tissue [157, 158] and accumulates in brain tumours [159].  Like phosphacan, bikunin contains 
disulphated embedded CS-D motifs within the repeating disaccharide region of its CS chain [91].  
Such motifs promote neurite outgrowth, suggesting that bikunin may also have similar roles to play 
in neural development.  Appican is another brain CS-proteoglycan [50, 160] produced by astrocytes 
[161], which direct neural development.  CS-E motifs embedded within the CS chains of appican 
[51] interact with neuroregulatory factors [52] inducing morphological change in C6 glioma cells 
and directed adhesion of neural cells to the ECM [53].  CS-E motifs also promote  chondrocytic 
differentiation of ATDC5 cells. ATDC5 cells produce monosulphated CS-A or disulphated 
disaccharides (CS-E) in their ECM proteoglycans. Exogenously added CS-E also affects 
chondrogenic differentiation of ATDC5 cells, promoting chondrogenic differentiation 
demonstrating the existence of cell surface receptors for CS-E [162].   Embedded CS-E in the CS 
side chains of growth plate perlecan also promote collagen fibrillogenesis [49]. 
 
 NG2 proteoglycan, phosphacan and syndecan-1-4 have roles in cellular regulation and 
tissue development, which may be of application in tissue repair strategies.  For example NG2 
proteoglycan stimulates endothelial cell proliferation and promotes migration during micro-vascular 
morphogenesis. NG2 is also expressed by chondroblasts and chondrocytes and acts as a cell surface 
2-VI collagen receptor conferring cellular motility and 41 integrin mediated cell spreading by 
activation of FAK and ERK1/ERK2 signalling cascades. A better understanding of the CS-
sulphation motifs and their binding partners and how these regulate cellular processes in tissue 
remodelling and repair may allow the development of improved therapeutic procedures in repair 
biology.  
 
5.1 The balance between stimulatory and inhibitory signals in neural development 
 SRPX2 (Sushi repeat protein, X linked 2) (Fig 2a) is a novel secreted CS-proteoglycan, 
which promotes synaptogenesis in the cerebral cortex and is found as an embedded domain in some 
members of the lectican proteoglycan family. The SPRX2 gene is a target of the foxhead box protein 
P2 transcription factor (FoxP2) that modulates synapse formation [163]. Mutations in SRPX2 causes 
Rolandic epilepsy and speech impairment (RESDX syndrome).  Interactome/cell surface 
binding/plasmon resonance studies have identified SRPX2 as a ligand for uPAR, the urokinase type 
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plasminogen activator (uPA) receptor [164].  uPAR knockout mice exhibit an enhanced 
susceptibility to epileptic seizures and anomalous cortical organization consistent with altered 
neuronal migration during brain development [165, 166]. uPAR is a crucial component of the 
extracellular plasminogen-plasmin system, which remodels the ECM during brain development. 
Cathepsin B and ADAMTS4 are also SRPX2 ligands and also likely participants in developmental 
processes in the brain [167].  ADAMTS-4 has been localised to regions of the spinal cord undergoing 
repair.  ADAMTS-4 degrades aggrecan and versican in the CNS thus removing the inhibitory signals 
provided by the CS side chains of these PGs [168, 169].   
 
Cathepsin B is a well known activator of pro uPA thus SRPX2 and its ligands represent a network 
of proteins with critical roles in brain development and specifically in the centres of speech and 
cognitive learning. The Rolandic and Sylvian fissures bisect the human cerebral hemispheres and it 
is the adjacent areas of the brain, which are responsible for speech processing. Ordered neuronal 
migration is therefore essential for the correct development of these areas of the brain. SRPX2 
protein expression occurs in neurons from birth and has central roles to play in developmental 
processes in the centres of speech and cognitive learning. Two mutations have been identified in 
SRPX2 in RESDX patients.  One mutation (N327S) results in altered glycosylation while a second 
mutation (Y72S) affects the first sushi domain of SRPX2 [170], 3D modelling indicates that the 
Y72S mutation affects an area of the SRPX2 core protein normally involved in protein-protein 
interactions [171]. Cultured cells from RESDX patients display alterations in the intracellular 
processing of proteins and likely misfolding which may have functional consequences [172].  
 
 Specific CS sulphation motifs are involved in interactions between neurons and glial cells 
to regulate the development and regeneration of the CNS. Migrating neurons are guided by glial 
cells through ECM proteoglycans they assemble such as phosphacan, and the CS-lectican 
proteoglycan family. Phosphacan promotes neurite outgrowth whereas versican, neurocan, and 
brevican inhibit this process thus collectively these proteoglycans  direct neurite growth. This is a 
function of their differing GAG CS sulphation motifs. CS-D motifs in phosphacan promote neurite 
outgrowth while lectican CS-A and CS-C motifs inhibits neuronal migration [152] and regulate 
neural tissue morphogenesis [153] [150, 173]. Glucuronyl transferase-1 knockout embryonic stem 
cells (ESCs) lack CS resulting in a significantly altered ability to differentiate and reduced ability to 
develop into pluripotent cell lineages [26].  HS maintains ESCs in a state primed for differentiation 
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however CS maintains ESC pluripotency and promotes ESC differentiation. Binding of CS-A and 
CS-E to E-cadherin to overcomes cell inhibitory inhibitory signals enhances ESC 
differentiation[26]. The highly charged CS-D and CS-E sulphate motifs can mimic HS in terms of 
growth factor and cytokine binding however the less highly charged CS-A and CS-C isomers should 
not be discounted in such interactions.  Surface plasmon resonance studies have demonstrated CS-
A and CS-C bind with significant affinity to midkine, pleiotrophin, HGF and stromal cell derived 
factor-1 but with a lower affinity than CS-D, CS-E and HS [174] regulating the growth, 
differentiation and migration of neural precursor cells [175]. Such lower affinity interactions may 
provide a more subtle control mechanism than the strong on-off signals supplied by HS.   FGF-2 
and EGF dependant proliferation of glial cells regulates neurogenesis during CNS development 
[176-178]. Chondroitin-6-sulphate synthesis is upregulated in the injured CNS, induced by injury 
related cytokines and enhanced in axon-growth inhibitory glia [179] and of relevance to nerve 
regeneration through glial scar formations [180].   
 
6. CS sulphation motifs and pathological remodelling of connective tissues 
 Several years ago [181, 182] it was noted that mAbs 3-B-3 (-) and 7-D-4 identified 
chondrocyte “cell-clusters” in pathological (osteoarthritic) canine and human articular cartilage and 
at that time these were considered a classical feature of the onset of late stage degenerative joint 
disease. In these early publications a lack of knowledge of stem/progenitor cells in cartilage and 
expression of proteoglycans (aggrecan) with CS GAG chains recognised by mAbs 3-B-3 (-) and 7-
D-4 were interpreted to indicate a failed, late-stage, attempt to repair cartilage and replacement of 
new proteoglycans in a matrix that had been extensively degraded by MMPs.  An alternative 
hypothesis now is that these ‘chondrocyte clusters’ arose from adult stem/progenitor cells in these 
tissues [183]. Tesche and Miosge [184, 185] showed that adult stem cell clusters were surrounded 
by a pericellular matrix containing perlecan.  This is also a feature of stem cell niches in foetal knee, 
hip, IVD and elbow cartilage [129-133, 186]. It is expected that in different connective tissues, the 
CS sulphation motifs will be present on different matrix and cell surface proteoglycans, if this is the 
case, an important feature of the stem/progenitor cell niche may be the sulphation of the GAGs 
rather than the core proteins to which they are attached.  Expression of different levels of GAG 
sulphotransferases in stem/progenitor cells would therefore also contribute to tissue repair [187-
189]. More recently, cell clusters within the superficial zone of healthy articular cartilage have been 
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shown positive for both Notch 1 and CD166 [190], cell surface markers that are synonymous with 
the stem cell niche environment [136, 191].  
6.1 CS expression and tumour development 
Neuroendocrine tumours with different degrees of histological differentiation have correlative 
alterations in associated CS but little change in HS. Normal stroma contains no staining with anti-
CS Abs while staining in tumour is significantly elevated and highest in advanced tumour grades 
[192].  CS-proteoglycan levels are elevated in liver cancer [193], renal [194], hepatocellular [195, 
196] and gastric carcinoma [197], pancreatic cancer [198] and in mammary tumours [199].  In 
gastric and pancreatic cancer non-sulphated and 6-sulphated CS predominate over other GAG 
isoforms and the GAG chains display a smaller hydrodynamic size than normal tissues. Elevated 
levels of 4- and 6-sulphated CS are found in renal cancer.  Decorin and versican levels are elevated 
7-27 fold in pancreatic cancer, and contain non-sulphated and 6-sulphated CS. This contrasts with 
the normal pancreas where DS is the predominant GAG decorating versican and decorin core 
proteins. Tumour proteoglycans have altered interactive properties further impairing the normal 
functional properties of tumour affected tissues. Proteoglycans and GAGs modulate cellular 
processes relevant to all stages of tumour progression, including cell proliferation, cell-matrix 
interaction, cell motility and invasive growth. HS, CS/DS and HA all have well documented roles 
in tumour pathobiology [200]. CS is abundantly present in the ECM in ovarian cancer. Alterations 
in the sulphation of CS also influences cancer development and its aggressive status. The CHST15 
gene is responsible for the biosynthesis of highly sulphated CS-E [269]. The single chain phage Ab 
GD3A11 to highly sulphated CS facilitates identification of biomarkers in aggressive tumour 
development. The GD3A11 epitope is minimally expressed in normal tissues but is intensely 
expressed in a number of ovarian cancer sub-types but not in benign ovarian tumours [201].  Serum 
over-sulphated CS levels measured using mAb WF-6 are also elevated in ovarian cancer and may 
also be a useful biomarker [202]. Silencing of CHST15 in-vitro and in a xenograft model of 
pancreatic cancer down-regulates tumour invasion in pancreatic ductal adenocarcinoma (PDAC). 
CS-E is detected in both tumour and stromal cells in PDAC and is considered to have multistage 
involvement in its development [203]. A single intra-tumoural injection of CHST15 siRNA almost 
completely silenced tumour growth providing evidence of the direct involvement of CHST15 in the 
proliferation of pancreatic tumour cells identifying a novel therapeutic target. The phage display 
antibody GD3G7 also reacts with the rare CS-E and DS-E epitopes in normal tissues, where DS-E 
epitope represents IdoUA-GalNAc (4,6-O-disulphate) [368]. CS-E is strongly up-regulated in 
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ovarian adenocarcinomas. Thus Ab GD3G7 is useful in defining tumour tissue alterations [204]. 
Quantitation of GAGs in colorectal tumour tissue using electrospray ionization mass spectrometry 
showed that neoplastic tissues displayed greater levels of CS and DS than non-neoplastic tissue 
where HS was decreased [205]. NEDD9 (CAS-L, HEF-1) cells have key roles in the migration and 
proliferation of MDA-MB-231 breast cancer cells [206]. Microarray studies in breast cancer 
samples demonstrate elevated CD44 and serglycin and down-regulation of syndecan-1, syndecan-2 
and versican whereas CHST11, CHST15 and CSGALNACT1 were all up-regulated in NEDD9 cells, 
an increase in CS-E attached to CD-44 was also evident in tumour cells.  Removal of CS using 
chondroitinase ABC inhibited colony formation by NEDD9 cells whereas exogenous application of 
CS-E enhanced NEDD9 cell proliferation and tumour development clearly demonstrating roles for 
CS-E in tumourogenesis [206]. A number of tumour cells express GAGs with alterations in 
sulphation level.  Altered expression of CS and HS on tumour cells has a key role to play in 
malignant transformation and tumour metastasis [207, 208]. Receptor for Advanced Glycation End 
products (RAGE) is a receptor for CS-E in Lewis lung carcinoma (LLC) cells [273, 278].  RAGE 
binds strongly to CS-E and HS and to LLC cells and has roles in tumour development. Serglycin is 
the major proteoglycan produced by multiple myeloma (MM) cells. Knockdown of serglycin 
dramatically attenuated MM tumour growth [209].  Tumours, which develop in serglycin 
knockdown animals, display lower levels of HGF and reduced blood vessel development indicating 
that serglycin has roles in angiogenesis.  The CS chains on serglycin are at least partly responsible 
for cellular attachment to CD44. Serglycin was originally considered to be a product of 
haematopoietic cells, recent studies have shown that it is also synthesized by a number of non-
haematopoietic cells [210].  Serglycin is expressed by tumour cells, promotes an aggressive 
phenotype and confers resistance to drugs and inactivation by the complement system. Serglycin 
promotes inflammatory conditions through inflammatory mediators, which are normally complexed 
in intracellular granules thereby contributing to tumour development. The CS-lectican proteoglycan 
versican accumulates in the tumour stroma and has key roles in malignant transformation and 
tumour progression. Elevated expression of versican in malignant tumours is associated with cancer 
relapse and poor clinical outcome in prostate, breast and many other cancer types. Versican (so 
named from ‘versatile’) regulates cell adhesion, proliferation, apoptosis, migration, angiogenesis, 
cell invasion and metastasis.  These processes involve interactions mediated by the CS and DS 
chains of versican and its G1 and G3 globular domains. Versican therefore represents a logical 
therapeutic target in tumour pathobiology [211].  Versican G3 domain regulates neurite growth 
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[212].  Versican Vo and V1 regulate neural crest cell migration [213]. Versican G3 domain promotes 
tumour growth and angiogenesis [214, 215].  
 
 CD44 regulates apoptosis in chronic lymphocytic leukaemia (CLL) and its expression is 
mediated by the tumour microenvironment. Interaction of CD44 with HA and CS protects CLL cells 
from apoptosis.  Specific antibodies to CD44 (IM7, A3D8) impair the viability of CLL cells and 
represent a potential therapeutic target [216]. CS chains in the microenvironment of breast cancer 
cells have been suggested as appropriate molecular therapeutic targets given that they promote many 
aspects of carcinogenesis in-vitro [217]. Dramatically elevated CS levels have been observed in the 
stromal microenvironment of many solid tumours. Intra-tumoural injection of chondroitinase ABC 
was ineffective in promoting primary tumour regression but led to development of secondary 
tumours indicating that the CS chains associated with primary tumours had a metastasis inhibitory 
role exploitable in therapeutic interventions. Cell surface HS and CS chains have roles in the 
infective stages of viral mediated carcinomas such as Merkel cell carcinoma, a highly lethal but rare 
form of skin cancer. HS and CS chains act as cellular receptors in the infective stages of Merkel cell 
poliomavirus.  Modulation or removal of such CS or HS entry points may provide an approach to 
combat viral attachment to cells during these initial infective stages [218]. CS on the surface of 
breast cancer cells function as P-selectin ligands.  CHST11 and CSPG4 are highly expressed in 
aggressive breast cancer cell lines and correlate with P-selectin binding levels. The CS chains of 
CSPG4 facilitate binding of P-selectin to highly metastatic breast cancer cell lines. Targeting of CS 
and its biosynthesis represents an attractive approach in anti-metastatic therapy [219, 220]. 
Therapeutic targeting of CSPG4 has been used to specifically target myeloma tumour cells using 
mAb based therapies [58, 221]. Adoptive transfer of genetically modified T cells is emerging as a 
powerful anti-cancer biotherapeutic.  CSPG4 is an attractive target molecule in this approach due to 
its high expression in cancer cells in several types of human malignancies but restricted distribution 
in normal tissues [222] and helps to minimise any potential toxic side effects using such approaches. 
T-cells expressing a CSPG4-specific chimeric antigen receptor offer the possibility of targeting a 
broad spectrum of solid tumours for which no curative treatment is currently available [222-224]. 
The treatment of rhabdomyosarcoma (RMS) remains particularly challenging, with metastatic and 
alveolar RMS offering a particularly poor prognosis. CSPG4 is specifically expressed on RMS cells. 
The immunotoxin αMCSP-ETA', specifically recognizes CSPG4 on the RMS cell lines RD, FL-
OH1, TE-671 and Rh30 and is internalized rapidly, induces apoptosis and kills RMS cells 
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selectively. Preliminary studies have demonstrated promising results with the specific binding of 
this immunotoxin to RMS primary tumours [225]. Deterioration of liver function in liver cancer is 
accompanied by an increase in the amount of CS-proteoglycans. This alteration in proteoglycan 
composition interferes with the physiologic function of the liver. Glypicans, agrin, and versican also 
play significant roles in the development of liver cancer [193]. CS-proteoglycans have essential 
roles to play in tissue morphogenesis and in cancer development involving interactions with 
growth factors, morphogens, cytokines, cell surface receptors, and a number of matrix proteins 
[226].  
 
 GAGs play vital roles in every step of tumour progression. Tumour samples with different 
degrees of histological differentiation demonstrate important alterations in the CS chains of a 
number of proteoglycans. Immunolocalisations conducted with anti-CS antibodies consistently 
showed normal stroma was negative whereas tumoural stroma were positive with elevated staining 
in the higher grade cancer samples while the tumour cells themselves were negative. Syndecan-2 
levels were low or undetectable in normal tissues but significantly elevated in endocrine tumours. 
Glypican-5 was overexpressed in high-grade tumours with epithelial differentiation, but not in 
neuroendocrine tumours. Normal neuroendocrine cells displayed positive cytoplasmic and 
membrane staining for glypican-1 but elevated expression in low-grade tumours and reduced in high 
grade tumours [192].  Use of a therapeutic CSPG4 specific antibody (225.28) enhanced and 
prolonged the inhibitory response of PLX4032 (Vemurafenib) in combination therapy suggesting 
Ab 225.28 may be useful as a delivery system in the treatment of melanoma [227]. 
 
7. CS sulphation motifs regulate cell behaviour - can they be used to promote tissue repair? 
 This review has demonstrated pivotal roles for CS-proteoglycans in developmental 
processes in cell migration, cellular recognition and tissue morphogenesis [1-4]. Novel CS 
sulphation sequences also occur in the functionally distinct layers of skin [228]; are associated with 
the long bone growth plates in endochondral ossification and occur at important growth zones in the 
developing intervertebral disc, diarthrodial joints and tendon [229, 230]. During lymphopoeisis, CS 
chains are also differentially modified at sites of B-cell differentiation and maturation [229, 231] 
and in the brain CS sulphation plays an important role in neurite outgrowth, synaptic plasticity and 
neurological development [232]. Accumulated evidence therefore points to specific GAG sequences 
in CS having roles in cell interactions and developmental processes. A greater understanding of 
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these processes through sustained basic research could eventually lead to their use in advanced 
therapeutic applications in regenerative medicine. With the advances in oligosaccharide synthesis 
methodology now available, the CS sulphation motifs discussed in this review can be synthesised 
and CS oligosaccharide microarrays prepared to answer structure-function questions relevant in 
tissue repair strategies. A number of lipid-derivatized CS oligosaccharides with well-defined 
sulphation features have been synthesised and used in CS oligosaccharide microarrays to 
characterise the preferred binding sequences of the anti-CS mAbs 2H6, MO225, 473HD and LY111 
[167] and to assess prospective binding partners (growth factors, cytokines) and many of the effects 
of these CS oligosaccharides on cellular behaviour have also been determined in-vitro.  This 
supports their therapeutic application in tissues such as the brain and CNS, and may lead to the re-
establishment of nerve function in glial scar formations.  
 
7.1 Development of smart CS-bioscaffolds to improve tissue repair 
 The development of CS-bioscaffolds and their applications with stem cells in cartilage, 
bone, cornea, skin and nerve repair strategies represent a significant advance in bioscaffold design 
and performance in tissue repair strategies. CS has indispensable roles to play in stem cell 
differentiation and attainment of pluripotency [26]. Accumulated evidence points to CS sulphation 
motifs having critical roles in cell interactions, cell differentiation, proliferation and matrix 
assembly. A greater understanding of these glyco-code mediated processes could lead to improved 
repair biology therapeutics. Cartilage is a particularly difficult tissue to repair and many biomatrices 
have been developed in order to perfect an effective repair strategy [233], these have focussed on 
MSCs as a therapeutic cell type. CS-bioscaffolds promote proliferation of bone marrow stromal 
MSCs and their differentiation to a chondrogenic phenotype appropriate for cartilage repair. 
Combinations of CS, gelatin, chitosan, HA incorporated into polyvinyl alcohol (PVA), polylactic-
co-glycolic acid (PLGA) hydrogels [233-237] have been developed. A thermoresponsive 
photopolymerizable CS hydrogel has been used to prepare a chondrocyte matrix suitable for 3D 
printing [234].  CS tethered on silk fibroin, silk-gelatin-CS-HA biocomposites or CS biomimetic 
scaffolds [238] have proved suitable for induction of a chondrogenic phenotype in MSCs [239, 240]. 
Porous CS-alginate foams and chitosan-gelatin-C6S-HA cryogels promote the chondrogenic 
differentiation of MSCs [241-243] as do CS-HA-Silk-lentiviral inserted TGF-3 gene, HA-CS-
Heparin-Collagen scaffolds, and multilayered 3D CS chitosan constructs [244-246].  
Atellocollagen-CS, collagen-CS-HA 3D hydrogels, cross-linked type II collagen-CS scaffolds [247-
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249], PLGA-gelatin-CS-HA-TGF-3 and elastic copolymer-CS-TGF-3 scaffolds provide superior 
induction of chondrogenic cells from seeded MSCs [250, 251].  
 
Fibrous tissue formed in response to implanted materials has been shown to contain CS [252], with 
increased infiltration of  inflammatory mast cells. The mast cell proteoglycans serglycin and 
perlecan display a 2-B-6 (-) epitope on their CS chains [121]. Like 3-B-3 (-), 2-B-6 (-) is not 
generated by chondroitinase ABC digestion. The presence of this 2-B-6 (-) epitope has previously 
been reported in osteoarthritic cartilage, however how the epitope is generated, or its function remain 
to be established [253]. Generation of this epitope is due to the action of a member of the 
hyaluronidase (HYAL) family, HYAL-1 or HYAL-4,  depolymerise CS via a hydrolytic cleavage 
reaction at the β1→4 disaccharide glycosidic linkage [254, 255]. HYAL-1 or HYAL-4 may also 
generate the 3-B-3 (-) ‘native’ CS epitope. The 2-B-6 (-) epitope, and production of HYAL-4 by 
mast cells are both associated with tissue remodelling and repair in inflammatory conditions.  
 
7.2 Cell surface CS-receptors and CS interactive molecules that control cellular behaviour 
 Only a few cell interactive oligosaccharide sequences in CS-DS have so far been identified 
due to inherent difficulties in decoding their complicated structures. CS-DS hexasaccharide and 
octasaccharide motifs, which facilitate interactions with heparin cofactor-II and pleiotrophin, have 
been determined [256-258]. A major difficulty in the identification of these interactive CS-DS 
modules is due to them not being a well defined saccharide sequence, but rather several 
heterogeneous modification patterns, the so called  ‘wobble CS-DS motifs’ [25].  The nomenclature 
for CS isoforms CS-A, CS-C, CS-D, CS-E, and DS, is confusing and misleading in that naturally 
occurring CS-A, for example, is not a homogenous polymer composed of CS-A disaccharide units 
only, but may contain a mixture of A, C, and unsulphated chondroitin units and embedded CS-D or 
CS-E motifs within the repeating disaccharide regions of CS-A GAG chains or the D-glucuronic 
acid can be epimerized to L-iduronic acid [259, 260]. HS has historically been considered to play 
more important roles in GAG-mediated cellular regulation than CS due to its higher propensity to 
interact with growth factors, morphogens and ECM components [261].  Recent studies have now 
demonstrated essential roles for CS–DS in a number of biological processes, especially in events, 
which regulate CNS development, and in tumourogenesis/metastasis.   
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 The soluble ecto-domain of PTPR β/ζ, phosphacan interacts with the cell surface receptor 
contactin-1 (Fig 9a).  Further cell signalling membrane proteins include the syndecan proteoglycan 
family (SDC 1-4), CSPG-4, betaglycan or endoglycan, these interact with cell surface receptors such 
as neuropilin-1, leukocyte common antigen-related phosphatase (LAR) and the related receptor 
protein tyrosine phosphatase β/ζ (Fig 9b, c).  The neuronal Nogo axonal guidance receptor family 
consist of three GPI-anchored receptors (NgR1, R2, R3) (Fig 9d, e) [262], the semaphorins, and 
neuropilins are further receptors which interact with CS-ligands (Fig 9f, g)  P75 is a transmembrane 
co-receptor which interacts with a number of receptors including the Nogo-1 receptor (NgR1) and 
acts as a signal transducer, converting signals initiated upon binding of myelin associated inhibitory 
proteins (MAIs) or CS-DS GAG to NgR1 converting this into intracellular signals via p75’s 
cytoplasmic domains and the Ras/MAPK and JNK pathways to inhibit neurite outgrowth.   
 
7.4 E-Cadherin 
 The cadherins are calcium-dependent type-1 transmembrane proteins which form adherens 
junctions ,binding cells tightly together within tissues and have essential roles to play during 
embryonic development and critical in the induction of stem cell pluripotency [263-266]. Cell 
adhesion is mediated by extracellular cadherin domains, intracellular cytoplasmic domains associate 
with a large number of adaptor and cytoskeletal signalling proteins which constitute the 
cadherin adhesome [267]. The cadherin membrane-spanning adherens junction proteins have crucial 
roles in cell–cell contact formation and are also connected to cytoplasmic proteins which regulate 
signalling pathways and relay information regarding cell interactions to the nucleus [268-272]. E-
cadherin and LRP 5/6 interact cooperatively with cell surface CSPGs and frizzled to regulate 
intracellular signalling through effects mediated by the catenin system which affects actin 
polymerisation/depolymerisation regulating ERK phosphorylation and cell signalling (Fig 10 a-b). 
CS-DS contributes to several signalling pathways and biological events [273]. A CS-E isoform binds 
strongly to Wingless/int-3a (Wnt-3a) and to a number of growth factors, neurotrophic factors, and 
cytokines in-vitro [274-276] (Fig 10c). Wnt signalling controls a number of developmental 
processes, tissue renewal and regeneration, and the development of several diseases, particularly 
cancers [274-276]. Specific arrangement of sulphation motifs on CS-DS chains modulate Wnt 
signalling and diffusion. Early stages of embryonic stem cell differentiation are promoted or 
repressed, by CS-E, but not by CS-A through Wnt/-catenin signalling pathways [275].  The 
migration of breast cancer cells in-vitro is reduced by CS-E, but not CS-DS [276]. CS-E regulates 
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type I collagen fibrillogenesis and expression, and is a positive regulator of breast carcinoma, 
through Wnt signalling [276]. Collectively, these findings provide insights into how cancer 
development is mediated through CS-E and Wnt/-catenin signalling. However, it is still unclear 
what specific sulphation pattern(s) or length of CS-E saccharide is required to activate and regulate 
such development processes. 
 
7.3 CS-E interactions with RAGE involved in tumour metastasis  
 The biosynthesis of stromal CS-DS proteoglycans is up-regulated in many tumours causing 
their accumulation in stromal tissues with attendant effects on tumour progression [277, 278]. The 
proportion of CS-E disaccharide units in CS-DS chains is elevated in ovarian and pancreatic cancers 
[212, 275], resulting in alterations in neoplastic growth and cell motility.  Tumour cell signalling is 
also controlled by VEGF and cleavage of CD44 [279, 280]. The stronger expression of disulphated 
CS-E disaccharide units on CS-DS chains on the surface of metastatic Lewis lung carcinoma (LLC) 
cells correlates with their invasive properties in lung tissue [281]. In the lung RAGE acts as a 
receptor for cell surface CS-DS chains containing CS-E units expressed by LLC cells [282] (Fig 
11a, b). RAGE recognizes CS-E unit containing decasaccharides [282], these markedly inhibit the 
pulmonary metastasis of LLC cells [281], most probably by competitive inhibition.  Binding of CS-
DS ligands to RAGE leads to downline effects on intracellular proteins such as Rap1 and PKC which 
effect the activation of NFB and CREB signalling  and transcriptional regulation (Fig 11c). 
 
8. Conclusions 
While advances in detection methodologies continue to improve the characterization of an ever-
expanding repertoire of complex glycans in small amounts of sample, certain unifying principles 
have emerged with regard to how these entities regulate cellular metabolism. The sulphate motifs 
within glycosaminoglycans represent a key information storage and transfer medium, which cells 
can interpret, to effect tissue homeostasis.  The glyco-code contained in glycosaminoglycans is an 
IT system which nature has developed over many hundreds of millions of years of evolution. 
However. despite the complexity and biodiversity of glycosaminoglycan structures it is the sulphate 
motifs which are key cell-directive players in the glyco-code and the sophisticated structures to 
which they are attached may be viewed as molecular scaffolds whereby varied planar orientations 
or densities of the sulphate groups can be explored to achieve optimal interactions with their 
respective ligands.  Significant inroads have been made in the sequencing of glycosaminoglycans 
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and encoded sequences linked with biological processes continue to be identified. A greater 
understanding of this glyco-code will undoubtedly continue to improve our understanding of the 
development and regulation of connective tissues and may lead to significant improvements in how 
this information is applied in advanced strategies in repair biology.   
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      Table  1. Form and Functions of CS/DS Proteoglycans  
 
Protein 
alternative name 
Gene 
Distribution Function Ref 
 
Aggrecan 
CSPG1 
ACAN 
 
Widespread in ECM, 
cartilage, tendon, IVD 
Tissue hydration, space-filling, weight bearing 
proteoglycan in cartilage, IVD, forms 
protective perineural nets with HA and 
tenascin-C, has, roles in heart development.  
[283, 284] 
 
Versican 
CSPG2 
VCAN 
 
Widespread in ECM, 
CNS 
So named as a "versatile " proteoglycan based  
on its ability to promote cell proliferation, 
differentiation, cell migration in tissue 
remodelling and in connective tissue 
morphogenesis  
[285-287]  
 
Neurocan 
CSPG3 
 
 
CNS 
Brain lecticans HA binding proteoglycans 
interactive with NCAM, Ng-CAM/L1.  
Modulate cell binding in CNS development 
and neurite outgrowth activity in CNS/PNS. 
Upregulated in glial scars, inhibits astrocyte 
and neuronal growth, may act antagonistically 
with other brain PGs to regulate neurogenesis.  
Primary astrocytes and neural cell lines bind 
brevican independently of HA, controlling 
infiltration of axons and dendrites into 
maturing glomeruli in brain development. 
 
 
 
 
[288, 289] 
 
 
NCAN 
 
 
Brevican 
CSPG7 
BCAN 
 
 
 
CNS, One of the most 
abundant brain 
proteoglycans 
 
 
 
 
 
Chondroitin sulphate-4 
NG2 
      CSPG4 
 
 
 
Widespread 
distribution in ECM 
and CNS with roles in 
development. Integral 
transmembrane 
proteoglycan. 
Found on the surface of immature 
oligodendrocyte and chondroblastic 
progenitor cells. Roles in cell-PCM 
stabilisation, cellular proliferation, 
migration, inhibits neurite outgrowth during 
axonal regeneration.  May sequester FGF-
2/PDGF.  CSPG4 is a collagen VI 
transduction receptor activating 
FAK/ERK1/ERK2. Widely expressed by 
tumour cells and is specifically targeted by 
therapeutic measures combatting 
tumourogenesis. up-regulated in spinal cord 
injury and in chondrogenesis 
 
 
 
 
[141] [56] 
 
Neuroglycan-C 
CSPG5 
 
CNS 
Transmembrane CS-proteoglycan bearing an 
EGF ECM domain, acts as an active growth 
factor and ligand for ErbB3, sixth member 
(neuroregulin-6) of the neuroregulin family. 
Contains CS-E, CS-C 
 
[290] 
[291] 
 
Syndecan-1 
SDC1, 
Syndecan-4 
SDC4 
Widespread 
distribution in 
vascular, epithelial 
and weight bearing 
connective tissues and 
brain 
CS-E chains found in Syndecan-1, 3.  Widely 
distributed cell surface CS and HS substituted 
PGs also containing CS-E and CS-C. Midkine 
interacts with CS-E motif and participates in 
neural development and repair but interacts 
weakly with CS-A and CS-C.   
[82, 292, 
293] 
 
 
 
 
Phosphacan 
PTPRZ1 
 
 
 
CS-KS-HNK-1 
proteoglycan, known 
as receptor-type 
tyrosine-protein 
phosphatase zeta 
(PTPR  
 
Widespread 
distribution in 
CNS/PNS 
CS-KS-HNK-1 proteoglycan also known as 
receptor-type tyrosine-protein phosphatase 
zeta (PTPR-
membrane protein with cytoplasmic tyrosine 
protein phosphatase, carbonic anhydrase and 
fibronectin type III domains. Alternative 
splice forms exist.  DSD-1 is the mouse 
homologue. Roles in embryonic spinal cord 
development/neurogenesis. Contains CS-D 
which promotes embryonic axonal growth in 
CNS in mice. 473HD CS epitope in 
phosphacan has roles in neural precursor cell 
proliferation [294]  
[147, 152, 
294, 295] 
 
Chondrocyte and 
SMC perlecan 
HSPG2 
CS/HS hybrid 
proteoglycan found in 
cartilage, IVD, 
CS replaces some HS chains in perlecan 
domain 1 in articular and growth plate 
cartilage, 4,6-disulphated CS found in growth 
plate perlecan regulates collagen 
[43, 44]  
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meniscus, tendon and 
blood vessels 
fibrillogenesis. Roles in ECM stabilisation, 
growth factor-receptor transfer  and activation. 
Cell proliferation and differentiation, cell 
signalling. 
 
 
 
Leprecan 
PRH1 
 
 
 
Basement membrane 
100kDa Leu-Pro enriched CS-proteoglycan of 
basement membrane of cardiac and skeletal 
muscle, central nervous system (cerebral 
cortex and cerebellum), intestinal tract, 
trachea, ear, skin, liver, and kidney. Localises 
to the vascular basement membrane/smooth 
muscle in each organ.  Also expressed in the 
notochord during embryonic chordate 
development. May also have roles in the 
secretory pathway and as a growth suppressor. 
[296-298] 
 
Thrombomodulin 
THBD 
 
Endothelial cell 
membrane 
Endothelial cofactor proteoglycan with roles 
in the thrombin induced activation of Protein 
C anticoagulant pathway.  
[299, 300] 
 
 
 
 
Decorin 
DCN 
 
 
Biglycan 
BGN 
 
 
 
CS substituted 
decorin and biglycan 
are found in bone, but 
DS forms are 
normally found in 
cartilage and skin 
 
 
 
 
 
 
Susceptibility gene in 
OA 
 
 
 
DS SLRP found in 
epiphyseal cartilage 
SLRPs have roles in ECM 
organisation/stabilisation/collagen  
fibrillogenesis.  Facilitates cell signalling 
through interaction with inflammatory 
cytokines (IL-1, TNF- and growth factors 
(BMPs, WISP-1) and their receptors (EGF-R, 
IGFIR) affecting cell proliferation, survival, 
adhesion, migration, matrix synthesis.  
Controls the bioavailability of TGF-
regulates tissue fibrosis. Biglycan interacts 
with complement system and TLR4 in innate 
immune regulation. 
 
[38, 301-
303] 
 
 
 
Asporin 
ASPN 
 
ASPN is unique among the SLRPs in not 
having a GAG at its N terminus but contains 
an Aspartic acid repeat region which binds 
TGF- BMP-2 to negatively regulate 
chondrogenesis and osteogenesis. 
 
 
[304] 
 
 
Epiphycan 
EPYC 
 
Epiphycan contains 7 LRRs instead of 10-11 
LRRs like other SLRP members, related to 
osteoglycin 
 
 
[305]  
 
Bikunin/ITI 
AMBP 
Liver serum serine 
proteinase inhibitor, 
also synthesised by 
IVD cells, 
chondrocytes and 
meniscal cells 
Stabilises the  condensed HA layer in growth 
plate hypertrophic region, and around oocytes, 
proteinase inhibitory activity, anti-bacterial, 
antiviral, anti-metastatic, immune-modulatory 
and growth promoting properties 
 
[91, 306, 
307] 
 
Appican 
APP 
 
Brain 
 
CS-A and CS-E brain proteoglycan (Amyloid 
precursor protein) 
 
[50-53, 
161] 
 
Sushi repeat protein 
X-linked 2 
SRPX2 
 
SRPX2 is a CS-
proteoglycan which is 
overexpressed in 
gastrointestinal cancer 
and has roles in 
synaptogenesis 
SPRX2 is significantly upregulated in colon 
cancer and its expression levels correlates with 
tumour aggressiveness. SRPX2 siRNA 
markedly down regulates -catenin, MMP-2 
and -9 expression reducing tumour  cell 
proliferation, adhesion and migration via the 
Wnt/-catenin pathway. SRPX2 promotes 
synaptogenesis in the cerebral cortex.  
Mutations in SRPX2 result in Roland epilepsy 
and speech impairment (RESDX syndrome).  
Cathepsin B, ADAMTS-4 and uPAR - binding 
partners of SPRX2 in neural tissues. 
[308, 309] 
 
 
[163-165, 
167, 171, 
308] 
 
interphotoreceptor 
matrix proteoglycan 2 
(SPACRCAN) 
IMPG2 
Eye 
interphotoreceptor 
matrix 
 
IMPG2, interphotoreceptor matrix 
proteoglycan-2 
[39] 
 
 
 
 
 
 
   
[120, 121] 
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Serglycin 
SRGN 
Mast cells, platelets, 
macrophages, T-
lymphpocytes, 
leucocytes 
 
Mast cell serglycin is substituted with heparin 
side chains, macrophage serglycin has CS 
(CS-A, CS-E) side chains 
 
Endoglycan 
PODXL2 
 
CD-34 sialomucin 
transmembrane 
proteoglycan family 
member 
 
 
Contains extensive substitution with sialic 
acid and N- and O- linked glycan 
 
[310] 
 
CD44 
CD44 
 
 
Miscellaneous 
Neuroendocrine cell 
granule-pro-hormones 
 
Dermcidin proteolysis 
inducing factor DCD 
 
Parathyroid secretory 
protein-1 
/Chromogranin-A 
 CHGA 
 
Cholecystokinin 
Pancreozymin 
CCK 
 
 
 
 
CD44 V3 splice 
variants bearing CS 
chains have reduced 
affinity for HA 
 
 
 
 
 
 
 
 
Neurons and 
endocrine cells 
 
CD44 binds Ezrin, fibrin/fibrinogen, 
fibronectin, HA, osteopontin, Selectins-P, -E, 
-L. Ubiquitous HA receptor 
 
 
 
 
 
 
Anion exchange, Chondroitinase ABC MS 
proteomics screen  used to identify 
intracellular CS-DS proteins.  Chromogranin-
A, Secretogranin-1, 2, 3. Dermcidin, 
Neuropeptide W, Cholecystokinin, granule 
bone marrow cell CS-PGs and collagen and 
calcium-binding EGF domain-containing 
protein-1. 
 
[311] 
 
 
 
 
 
 
 
 
 
 
 
[312-321] 
 
Abbreviations: CNS, central nervous system; NCAM, neural cell adhesion molecule; PCM, pericellular 
matrix; FAK, focal adhesion kinase; ERK, extracellular regulated kinase; LRR, leucine rich repeat; SLRP, 
small leucine repeat proteoglycan: TLR4, Toll-like receptor-4, MS, mass spectrometry 
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Legends to Figures 
Figure 1. Organisation of GAG saccharides in full length, partially depolymerised, terminal (a) and 
stub epitopes (b) of the CS side chains of proteoglycans and in the GAG disaccharides in CS  types 
A, B, C, D, E (c) and simplified diagrams of the sulphate presentations in a typical CS side chain 
(e-g) In the example shown the chain is terminated in a 3-B-3(-) epitope and contains internal 7-D-
4 and 4-C-3 epitopes as shown.  A 3-B-3(+) stub epitope attached to the linkage tetrasaccharide is 
also shown, this epitope is generated by chondroitinase ABC.  The CS side chains can also be 
terminated in an alternate 2-B-6(-) epitope and have a 2-B-6(+) stub epitope. 
 
Figure 2.  Diagrammatic representation of of the sub-domain structural organisation of SRPX2 
(Sushi repeat protein, X linked 2) and members of the hyalectan family (a), Decorin and biglycan 
SLRP members (b) and the inter photoreceptor ECM proteoglycan SPACRCAN (c).  SUSHI 
complement control protein modular data was obtained from the public SMART database 
(http://smart.embl-heidelberg.de/).   
 
Figure 3. Structural organisation of cell associated CS-proteoglycans.  CSPG4 (a), thrombomodulin 
(b), RPTP/Phosphacan (c), syndecan family (d), and a CS substituted variant of the HA receptor 
CD44 (e).  Abbreviations not covered in key, ED, extracellular domain; TMD, transmembrane 
domain; CD, cytoplasmic domain.   
 
Figure 4. Organisation of the Kunitz protease inhibitor CS-proteoglycan, bikunin (a), type IX 
collagen (b), and testican, seminal plasma CS-proteoglycan (c). 
 
Figure 5. Diagrammatic CS-proteoglycans assembled into protective perineural nets in brain 
tissue (a) and ternary link-protein stabilised macro-aggregate structures with hyaluronan in 
articular cartilage which convey important hydrodynamic weight bearing and self lubricative 
properties to this tissue. 
 
Figure 6.  Confocal immunolocalisation of the 4C3 (a) and 7D4 (b) native CS sulphation motifs and 
perlecan using anti-domain IV antibody A7L6 (c) in human foetal (14 week gestational age) knee 
tibial cartilage. Cell nuclei are stained red with propidium iodide in (a) and (b) and with DAPI in 
(c).  The primary antibody localisations were stained green using FITC conjugated anti mouse or rat 
IgG.  Perlecan identifies stem cell niches in the surface regions of the developing cartilage.  Figure 
modified from [130] 
 
Figure 7. Perlecan and 4C3/7D4 immunolocate the perichondrial stem cell niche and activated 
progenitor cells involved in foetal elbow joint development. Immunolocalisation of perlecan and 
the CS sulphation motifs 4C3 and 7D4 using indirect fluorescent confocal microscopy of human 
foetal elbow (14 week gestational age). Perlecan is immunolocalised to the outer layers of the 
perichondrium (a, b) while the  7D4 (c-e) and 4C3 CS sulphation motifs (f-i) are located on cell 
associated proteoglycans deeper in the elbow cartilage rudiment and in the surface regions of the 
interzone cartilage of the developing elbow joint (f-i). 
 
Figure 8.  Focal expression of perlecan (a) and  7-D-4 CS sulphation motif (b) in foetal human  
paraspinal blood vessels.  Perlecan is a well known vascular HS-proteoglycan, produced by 
endothelial cells.  The 7-D-4 CS sulphation motif is focally expressed in the lumenal surfaces of 
these small blood vessels (b) and may provide evidence of a vascular progenitor cell population 
directed by signals from pericytes on the abluminal surfaces of these vessels (c).  Diagram of a 
small capillary showing the relationship of the endothelial cells and pericytes (d, e).  Type IV 
collagen delineates the blod vessel the pericyte resides on (f) while NG2 proteoglycan is a pericyte 
marker (g). 
 
Figure 9. Neuronal cell CS-interactive surface molecules with regulatory roles in neuronal 
development. Contactin-1 (a), leukocyte common antigen-related (LAR) tyrosine phosphatase 
receptor (b), protein tyrosine phosphatase receptors (PTP- and PTP-c -1 and 
3 (NgR1 and NgR3) (d, e), semaphorin-5A (Sem 5A) (f) and neuropilin-1 (NRP-1) (g). 
 
Figure 10.  CS-Interactive properties of E-cadherin (a), syndecan proteoglycan family (b) and the 
frizzled LRP-5/6 co-receptor complex (c) and resultant effects on cytoskeletal re-organisation  and 
gene regulation.   
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Figure 11. Interactive properties of CS-DS GAG chains of proteoglycans (a), HMBG1, AGEs, S100 
proteins and amyloid peptides with the extracellular domains of the RAGE receptor and effects on 
cytoskeletal proteins (b), activation of NFB and CREB  transcriptional regulation (c). 
 
 
